September 25, 2017 04:00 PM EDT
R&D

Pro­QR spot­lights the most en­cour­ag­ing re­sults from a mixed snap­shot of ef­fi­ca­cy for cys­tic fi­bro­sis

John Carroll

Editor & Founder

Ex­ecs at Pro­QR Ther­a­peu­tics $PRQR are do­ing their lev­el best this af­ter­noon to ac­cen­tu­ate the pos­i­tive in their ear­ly snap­shot of the im­pact its lead …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times